These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 11876511)
1. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Calza L; Manfredi R; Chiodo F Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511 [TBL] [Abstract][Full Text] [Related]
2. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. Calza L; Manfredi R; Chiodo F AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532 [TBL] [Abstract][Full Text] [Related]
3. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. Manfredi R; Chiodo F J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549 [TBL] [Abstract][Full Text] [Related]
4. Management of protease inhibitor-associated hyperlipidemia. Penzak SR; Chuck SK Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985 [TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia associated with protease inhibitor therapy. Echevarria KL; Hardin TC; Smith JA Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916 [TBL] [Abstract][Full Text] [Related]
6. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. Calza L; Manfredi R; Colangeli V; Tampellini L; Sebastiani T; Pocaterra D; Chiodo F AIDS; 2005 Jul; 19(10):1051-8. PubMed ID: 15958836 [TBL] [Abstract][Full Text] [Related]
8. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia]. Hirsch HH; Battegay M Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856 [TBL] [Abstract][Full Text] [Related]
9. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F; HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977 [TBL] [Abstract][Full Text] [Related]
10. Management of dyslipidemia in patients with HIV disease. Manfredi R Clin Microbiol Infect; 2000 Nov; 6(11):579-84. PubMed ID: 11168060 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961 [TBL] [Abstract][Full Text] [Related]
12. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878 [TBL] [Abstract][Full Text] [Related]
14. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Calza L; Manfredi R; Chiodo F Int J Antimicrob Agents; 2003 Aug; 22(2):89-99. PubMed ID: 12927947 [TBL] [Abstract][Full Text] [Related]
15. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Caramelli B; de Bernoche CY; Sartori AM; Sposito AC; Santos RD; Monachini MC; Strabelli T; Uip D Braz J Infect Dis; 2001 Dec; 5(6):332-8. PubMed ID: 11980596 [TBL] [Abstract][Full Text] [Related]
16. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062 [TBL] [Abstract][Full Text] [Related]
17. Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy. Geraix J; de Souza ME; Delatim FC; Pereira PC Braz J Infect Dis; 2006 Jun; 10(3):159-64. PubMed ID: 17568845 [TBL] [Abstract][Full Text] [Related]
18. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397 [TBL] [Abstract][Full Text] [Related]
19. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625 [TBL] [Abstract][Full Text] [Related]
20. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children. Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP; AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]